Moderna investors prepare for a phase 3 reveal
Intismeran autogene’s Interpath-001 trial reads out this year.
Neok plays a high-risk bispecific conjugate game
Armed with $75m the company takes a risky asset into the clinic.
Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
One Genmab Rybrevant challenge is rendered moot
GEN1286 looks dead, though MCLA-129 continues for now.
Two more in vivo Cars head for the clinic
New first-in-human study initiations feature yet more in vivo Car assets.
Licensing analysis: Takeda saves the day
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
